Please login to the form below

Not currently logged in
Email:
Password:

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Venclexta

Safety concerns could hit blockbuster expectations

Keytruda adds another NSCLC approval in Europe

Merck and Co - US headquartersSquamous NSCLC completes first-line dominance

CHMP recommends new Keytruda dosing schedule

merck-keytruda-pembrolizumab-melanomaWill apply to eight indications across five tumour types

Roche gets EU nod for much-expanded Hemlibra label

HemlibraDrug is now suitable for all age groups with multiple dosing options

More Brexit chaos as government suffers more defeats

UK parliament rejects a no-deal Brexit

NICE partially clears Darzalex combo in blood cancer

DarzalexApproved in second-line use under CDF

Brexit deal defeated again, crucial no-deal vote awaits

Brexit Cut OutUK pharma urges no-deal to be ruled out

Trump budget targets rebates, out-of-pocket costs

US president elect Donald TrumpBiotech sector welcomes end to rebates, but worries about Medicare cuts

23andMe to offer type 2 diabetes testing kit

23andme genetic researchNew report is powered by data from the company’s customers

Brexit‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

Brexit means pharma must review its intellectual property rights across Europe

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics